Humira® (adalimumab) (DrugBank: Adalimumab)
16 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
19 | ライソゾーム病 | 0 |
37 | 膿疱性乾癬(汎発型) | 0 |
40 | 高安動脈炎 | 0 |
41 | 巨細胞性動脈炎 | 0 |
46 | 悪性関節リウマチ | 1 |
56 | ベーチェット病 | 0 |
84 | サルコイドーシス | 0 |
96 | クローン病 | 0 |
97 | 潰瘍性大腸炎 | 0 |
151 | ラスムッセン脳炎 | 0 |
160 | 先天性魚鱗癬 | 0 |
164 | 眼皮膚白皮症 | 0 |
222 | 一次性ネフローゼ症候群 | 0 |
226 | 間質性膀胱炎(ハンナ型) | 1 |
269 | 化膿性無菌性関節炎・壊疽性膿皮症・アクネ症候群 | 0 |
271 | 強直性脊椎炎 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2007-000082-38-DK (EUCTR) | 24/05/2007 | 26/03/2007 | The OPERA Study. Optimized treatment algorithm in early rheumatoid arthritis: Methotrexate and intra-articular glucocorticosteroid plus adalimumab or placebo in the treatment of early rheumatoid arthritis. A Randomised, double-blind and placebo-controlled, two arms, parallel group study of the additive effect of adalimumab concerning inflammatory control and inhibition of erosive development. - The OPERA Study | The OPERA Study. Optimized treatment algorithm in early rheumatoid arthritis: Methotrexate and intra-articular glucocorticosteroid plus adalimumab or placebo in the treatment of early rheumatoid arthritis. A Randomised, double-blind and placebo-controlled, two arms, parallel group study of the additive effect of adalimumab concerning inflammatory control and inhibition of erosive development. - The OPERA Study | In early RA methotrexate and intra-articular glucocorticoid in combination with adalimumab is better than methotrexate and intra-articular glucocorticoid in achieving control of the disease as assessed by DAS28 < 3.2. MedDRA version: 9.1;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis | Trade Name: Humira (adalimumab) Product Name: Humira® (adalimumab) Product Code: 2593 INN or Proposed INN: Adalimumab | Aarhus University Hospital, Denmark | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 4 | Denmark |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01295814 (ClinicalTrials.gov) | March 2011 | 14/2/2011 | Efficacy Study of Adalimumab to Treat Interstitial Cystitis | An Investigator Initiated, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of Humira® (Adalimumab) For The Treatment of Interstitial Cystitis(IC) | Interstitial Cystitis | Drug: Adalimumab;Other: inactive drug | ICStudy, LLC | Abbott | Completed | 18 Years | 65 Years | All | 43 | Phase 3 | United States |